t
| TIDM | AMS |
| Share Price | 281.00p0.00% |
| Market Cap | £617.09m |
Advanced Medical Solutions Group plc held its Annual General Meeting on 31 May 2023 at 11:00 am. During the meeting, CEO Chris Meredith was scheduled to give a short presentation, with no new material information provided. The Group stated that the results of the AGM would be announced to the London Stock Exchange and placed on its website following the conclusion of the meeting.
| Date | 31 May 2023 |
| Time | 07:00:03 |
| Category | AGMs and other meetings |
| ID | 0782B |
31 May 2023
("AMS" or the "Group")
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, will hold its Annual General Meeting at 11.00 am today at the offices of Investec Bank plc, 30 Gresham Street, London, EC2V 7QP.
Chris Meredith, AMS's Chief Executive Officer, will give a short presentation at the Annual General Meeting. No new material information will be provided.
The results of the AGM will be announced to the London Stock Exchange and placed on the Group's website, in the usual way, as soon as practicable after the conclusion of the AGM.
- Ends -
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: +44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations |
|
|
|
|
|
Consilium Strategic Communications |
Tel: +44 (0) 20 3709 5700 |
|
Matthew Neal / Lucy Featherstone |
|
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: +44 (0) 20 7597 5970 |
|
Gary Clarence / David Anderson |
|
|
|
|
|
HSBC Bank PLC (Broker) |
Tel: 44 (0) 20 7991 8888 |
|
Sam McLennan / Joe Weaving / Stephanie Cornish |
|
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.
AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Austria, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see www.admedsol.com.